Grom, Alexei A.
Canna, Scott W.
Abu-Arja, Rolla F.
Sinha, Rashmi
Peixoto, Luciana
Cannizzaro, Elvira
Chandrakasan, Shanmuganathan
Driest, Kyla
Marsh, Rebecca
Neven, Bénédicte
Onel, Karen
Prahalad, Sampath
Prockop, Susan
Quartier, Pierre
Roth, Johannes
Schulert, Grant
Silva, Juliana M.F.
Wall, Donna
Zeilhofer, Ulrike
Article History
First Online: 5 January 2024
Declarations
:
: Not applicable.
: All authors have reviewed the manuscript and provided their consent to publish. All the patients mentioned in the manuscript gave their permissions to use full names.
: AAG received research grants from Novartis and Sobi; consulting fees from Novartis and Sobi; royalties from UpToDate Inc. and payment for development of CME slide presentation on MAS from Clinical Viewpoints. SWC received investigator-initiated research grants from Histiocytosis Association; consulting fees from Simcha Therapeutics, Apollo Therapeutics, SOBI; received payment for expert testimony from Parker Poe Adams & Bernstein LLP; received payment for lectures and educational events from PracticePoint communications and SOBI. RA, RS, LP, EC, BN, JR, JMFS, DW & UZ have no conflicts of interest or competing interests to declare. SC received consulting fees from SOBI (SAB). KD has no conflicts of interest or competing interests to declare. RM participated on the Advisory Board of SOBI and Horizon. KO received funding from CARRA (Childhood Arthritis and Rheumatology Research Alliance) for attending meetings and/or travel. SP participated in the Macrophage Activation Syndrome Adjudication Committee, Novartis Pharma, 2016–2022; and royalties from Op Med Fellow for Doximity Inc. SP received investigator-initiated research grants from PIDTC C-SIDE NIH Study Grant; consulting fees from CellEvolve (no fees), SmartImmune, ADMA; royalties from IP related to the development of 3rd party VSTs with all rights assigned to Memorial Sloan Kettering Cancer Center; received payment for lectures and educational events from Regeneron and Pierre Fabre; participated in Advisory Board from Atara Biotherapeutics, Stanford Trial Specific DSMB and NYBC Cord Blood Trial DSMB; received support for the conduct of clinical trials through Boston Children’s Hospital from Atara Biotherapeutics and Allovir. PQ received consulting payments from Abbvie, Amgen, BMS, Chugai Roche, Novartis, Novimmune, Pfizer and Sweedish Orphan Biovitrum; received funding for attending meetings and travel from BMS, Chugai-Roche, Novartis and Pfizer; and participated in a data safety monitoring board for Sanofi. GS received investigator-initiated research grants from IpiNovyx; and received consulting fees from Novartis and SOBI.